Previous 10 | Next 10 |
home / stock / bior / bior articles
Shares of NetEase, Inc. (NASDAQ:NTES) fell during Friday's session after the company reported worse-than-expected first-quarter revenue. NetEa...
Shares of Ross Stores, Inc. (NASDAQ:ROST) rose sharply in today's pre-market trading after the company reported better-than-expected earnings ...
Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on devi...
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quar...
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delive...
Monetization of legacy asset brings in $3 million in nondilutive capital Convertible notes exchange brings in another $2.8 million in new capital ...
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. Helix Energy posted ...
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic deliver...
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomi...
News, Short Squeeze, Breakout and More Instantly...
Biora Therapeutics Inc. Company Name:
BIOR Stock Symbol:
NASDAQ Market:
Biora Therapeutics Inc. Website:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...